Tuberculosis among foreign-born persons in the United States

JAMA

Volumn 300, Issue 4, 2008, Pages 405-412

  Cain, Kevin P ^a   Benoit, Stephen R ^a   Winston, Carla A ^a   Mac Kenzie, William R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

AFRICA; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; HUMAN; IMMIGRANT; IMMIGRATION; MAJOR CLINICAL STUDY; MORBIDITY; PERU; PHILIPPINES; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SOUTHEAST ASIA; SPUTUM SMEAR; SURVIVAL; TUBERCULOSIS; UNITED STATES; VIET NAM;

EID: 47849130608     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.4.405     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2006. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2007.
2. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(4 pt 2):S221-S247.
3. Geiter L. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: Institute of Medicine, National Academy Press; 2000.
4. Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med. 2007;175(1):75-79.
5. Chin DP, Deriemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in US-born and foreign-born persons. Am J Respir Crit Care Med. 1998;158(6):1797-1803.
6. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med. 2002;346(19):1453-1458.
7. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med. 1999; 130(12):971-978.
8. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med. 2008;177(3):348-355.
9. Cain KP, Mac Kenzie WR. Editorial commentary: overcoming the limits of tuberculosis prevention among foreign-born individuals: next steps toward eliminating tuberculosis. Clin Infect Dis. 2008;46(1):107-109.
10. Deardorff KE, Blumerman LM. Evaluating components of international migration: estimates of the foreign-born population by migrant status in 2000: table 2: 'true' level estimates of the foreign-born population by migrant status in 2000: baseline. US Census Bureau Web site. http://www.census.gov/population/ www/documentation/twps0058.html. Accessed June 8, 2008.
11. US Census Bureau American FactFinder. Selected characteristics of the native and foreign-born populations. http://factfinder.census.gov/servlet/ STTable?_bm=y&-geo_id=01000US&-qr_name=ACS_2006_EST_G00_S0501&- ds_name=ACS_2006_EST_G00_&-redoLog=false. Accessed June 8, 2008.
12. US Department of Homeland Security, Office of Immigration Statistics. Yearbook of Immigration Statistics 2006. http://www.dhs.gov/xlibrary/ assets /statistics/yearbook/2006/OIS_2006_Yearbook.pdf. Accessed June 10, 2008.
13. US Census Bureau. American Community Survey. http://www.census.gov/acs/ www/. Accessed June 8, 2008.
14. US Census Bureau. American Community Survey 2005 public use microdata (PUMS) code lists: place of birth code. http://www.census.gov/acs/www /Products/PUMS/C2SS/CodeList/2005/PlaceBirth.htm. Accessed June 8, 2008.
15. Zuber PL, McKenna MT, Binkin NJ, Onorato IM, Castro KG. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997;278(4) 304-307.
16. Iseman MD. A Clinician's Guide to Tuberculosis. Baltimore, MD: Lippincott, Williams & Wilkins; 2000.
17. Centers for Disease Control and Prevention. CDC Immigration Requirements: Technical Instructions for Tuberculosis Screening and Treatment. Atlanta, GA: US Dept of Health and Human Services; 2007.
18. Centers for Disease Control and Prevention. 1991 Technical Instructions for Medical Examination of Aliens. Atlanta, GA: US Public Health Service; 1991.
19. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(rr-15):1-47.
20. Morán-Mendoza O, Marion SA, Elwood K, Patrick DM, FitzGerald JM. Tuberculin skin test size and risk of tuberculosis development: a large populationbased study in contacts. Int J Tuberc Lung Dis. 2007; 11(9):1014-1020.
21. Rajagopalan S. Tuberculosis and aging: a global health problem. Clin Infect Dis. 2001;33(7):1034-1039.
22. Rose DN, Schechter CB, Fahs MC, Silver AL. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis. Am J Prev Med. 1988; 4(2):102-109.
23. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. JAMA. 1986; 256(19):2709-2713.
24. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a riskbenefit and cost-effectiveness analysis. Ann Intern Med. 1997;127(12):1051-1061.
25. Schechter CB, Rose DN, Fahs MC, Silver AL. Tuberculin screening: cost-effectiveness analysis of various testing schedules. Am J Prev Med. 1990;6 (3):167-175.
26. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest. 1993;103(6):1670-1674.
27. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J. 2005;25(6):1107-1116.
28. Goldberg SV, Wallace J, Jackson JC, Chaulk CP, Nolan CM. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis. 2004; 8(1):76-82.
29. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis. 2003;7(12)(suppl 3):S384-S390.
30. Parsyan AE, Saukkonen J, Barry MA, Sharnprapai S, Horsburgh CR Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect. 2007;54(3):262-266.
31. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 2005; 353(10):1008-1020.
32. Centers for Disease Control and Prevention; American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(31):735-739.
33. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006; 173(8):927-931.
34. Maloney SA, Fielding KL, Laserson KF, et al. Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam. Arch Intern Med. 2006;166 (2):234-240.
35. Centers for Disease Control and Prevention. 2007 Technical instructions for tuberculosis screening and treatment for panel physicians. http://www.cdc.gov/ncidod/dq/panel_2007.htm. Accessed June 26, 2008.